Estrogen-Induced Uterine Vasodilation in Pregnancy and Preeclampsia

Yan Li¹, Baoshi Han², Alejandra Garcia Salmeron³, Jin Bai³, Dong-bao Chen³,*

Abstract
Normal pregnancy is associated with dramatically increased estrogen biosynthesis whose role is believed to raise uterine blood flow to facilitate the bi-directional maternal-fetal exchanges of gases (O₂ and CO₂), to deliver nutrients, and exhaust wastes to support fetal development and survival. Constrained uterine blood flow in pregnancy is a leading cause of preeclampsia with fetal growth restriction, rendering investigations of uterine hemodynamics to hold a high promise to inform pathways as targets for therapeutic interventions for preeclampsia. The mechanisms of estrogen-induced uterine vasodilation in pregnancy have long been attributed to enhanced endothelium production of nitric oxide, but clinical trials targeting this pathway that dominates uterine hemodynamics have achieved no to little success. Emerging evidence has recently shown a novel proangiogenic vasodilatory role of hydrogen sulfide in regulating uterine hemodynamics in pregnancy and preeclampsia, provoking a new field of perinatal research in searching for alternative pathways for pregnancy disorders especially preeclampsia and intrauterine growth restriction. This minireview is intended to summarize the nitric oxide pathway and to discuss the emerging hydrogen sulfide pathway in modulating estrogen-induced uterine vasodilation in pregnancy and preeclampsia.

Keywords: Estrogens; Uterine vasodilation; Nitric oxide; Hydrogen sulfide; Pregnancy; Preeclampsia

Introduction
Normal pregnancy is associated with profound uterine artery (UA) dilation, reflected as ∼20–50-fold rises in uterine blood flow (UtBF) in late pregnant (P) vs. nonpregnant (NP) state, resulting in a large volume of maternal blood to be delivered to the maternal-fetal interface.¹⁻³ UtBF carries out the bidirectional maternal-fetal gas (ie, O₂ and CO₂) exchanges and provides the sole nutrient sources to support fetal and placental growth and survival.²⁻⁴ Abnormal UA Doppler flow is linked to preeclampsia¹ and constrained UtBF results in intrauterine growth restriction (IUGR),⁵,⁶ clearly demonstrating that UtBF is the rate-limiting factor for pregnancy health. Investigation of the mechanisms and pathways controlling UtBF, including the NO pathway that dominates the field of perinatal research in searching for alternative pathways for pregnancy disorders especially preeclampsia and IUGR.

Three periodic rises in UtBF occur in pregnancy; the first is associated with vasodilation and initiation of an increase in microvascular volume probably due to ovarian hormones, that is, estrogen and progesterone, which are necessary for optimizing the intrauterine environment for embryo implantation. Once the embryo is implanted and during placenta de novo formation of the placental vascular bed further remodels the maternal uteroplacental vascular bed, resulting in the second up to 2–4-fold rise in UtBF during this time in ovine pregnancy. The third exponential rise in UtBF occurs in the third trimester of gestation, which is essential for the nutrient delivery required for the exponential fetal growth that occurs at this time and maintenance of fetal well-being. This third peak rise in UtBF is due to vasodilation of the maternal UAs because at the time the uterine vascular bed exhibits minimal growth although the fetal placental vascular bed continues to grow.⁷

Decades of extensive studies have identified many endocrine regulatory pathways and UA local autocrine and paracrine factors that regulate uterine hemodynamics, including steroid hormones estrogen and progesterone, angiogenic growth factors, and endothelium-derived vasodilators such as nitric oxide (NO). Unfortunately, clinical trials targeting all known pathways controlling UtBF, including the NO pathway that dominates the field since the 1990s, have to date achieved no to little success. Inadequate understanding of how UA hemodynamics is regulated during normal pregnancy and how this is impaired in preeclampsia must be blamed for this major obstacle in developing effective treatments for preeclampsia with IUGR. Nonetheless, more studies to identify new
pathways that contribute to the physiological UA vascular adaptations to normal pregnancy and their maladaptations to preeclampsia are warranted. This minireview is intended to discuss uterine hemodynamic regulation in normal pregnancy and preeclampsia with a focus on the physiological roles of estrogens and the underlying mechanisms.

**Hemodynamic adaptations of UA in normal pregnancy**

Once conceived, the blood volume and flow rate in the main UAs increase gradually with the placental and fetal growth rates in the first and second trimesters; however, in the third trimester, the flow rate explodes proportionally so that a huge amount of blood is delivered to perfuse the placenta, essentially keeping pace with the exponential fetal growth rate. This is evidenced by the fact that compared to 1%–2% of total cardiac output is distributed to the uterine circulation in NP ewes, approximately 15%–20% of total cardiac output is distributed to the uterine circulation in late (day 130 in gestation, term ~145 days, equivalent to the third trimester in humans) pregnant ewes. The blood delivered from the UA to the maternal-fetal unit provides the sole sources of nutrients and O₂ respiratory gas (CO₂) of the fetus can be exhausted.

The mother parallel circulate the low oxygen blood back to the survival during pregnancy. Meanwhile, the uterine veins in needed to support fetal and placental development and survival during pregnancy. Therefore, the uterine circulation is the lifeline for the fetus and UtBF is the rate-limiting factor for maternal well-being during pregnancy. To accommodate the dramatic pregnancy-dependent increase in UtBF, the UAs must undergo significant structural and functional changes adaptive to pregnancy.

In eutherian mammals including humans, UAs arise from the internal iliac arteries. Blood delivered by these arteries, joined by a blood supply from the ovarian arteries, are the principal transportation system for delivering the oxygen/nutrient-rich arterial blood to the accuate branches within the myometrium and to the radial arteries continuing as the distal spiral arteries in the uterine endometrium. Collectively these vessels with descending sizes form the uterine vascular system, composed of endothelial cells (ECs) covering the inner luminal surface, vascular smooth muscle cells (SMCs) forming the thick layer of vessel wall, and extracellular matrix that stabilizes the vessels. During pregnancy, UA is remodeled to be with increased lumen diameter and length and reduced myogenic tone leading to lower vascular resistance, thus resulting in increased UtBF. Pregnancy-dependent UA vascular remodeling has been recently detailed in an excellent review article by Osol and Moore, in which they have also discussed the underlying mechanisms.

**Estrogen-induced UA vasodilation in pregnancy**

During the menstrual cycle, UtBF increases gradually from early or middle proliferative to secretory phase, from 22.4 ± 7.3 mL/min in the proliferative phase to 30.7 ± 13.7 mL/min in secretory phase, in association with maximum perfusion occurring in the mid-secretory phase in NP women. Interestingly, blood flow in radial arteries does not parallel the changes in UtBF. The regional changes in blood flow in the uterine vascular tree indicate that not only are vascular adaptations in the main UAs and thus UtBF under the control of specific mechanisms but also changes in steroid hormones (ie, estrogens and progesterone) are speculated to be critical physiological regulators of UtBF during the menstrual cycle. There are, however, conflicting findings regarding the correlation of UtBF with maternal circulating estradiol and progesterone in the menstrual cycle. For example, some studies reported no significant correlation of serum estradiol with uterine hemodynamics and others even reported a reduction in UtBF during the follicular phase when serum estradiol levels are high. Although the exact mechanisms regarding how UtBF varies during the menstrual cycle require further investigation, color Doppler ultrasound examination in women has proposed a role of local factors of the dominant follicle that reduce ovarian artery blood flow, indirectly causing a decrease in UtBF in the follicular phase.

In primates and humans, pregnancy-associated rises in UtBF are associated with a dramatic up to a 1000-fold increase in maternal plasma total estrogens, which are predominantly produced by the placenta in the last two-thirds of pregnancy. However, the predominant estrogens produced in pregnancy are relatively weak compared with estradiol-17β (E₂β) because estriol (E₃) is the major estrogens in pregnant women and estrone (E₁) plus sulfoconjugated estrogens are the major estrogens in ovine pregnancy. The purpose for this enhanced estrogen synthesis remains unclear; but it is believed to play a key role in modulating maternal cardiovascular changes adaptive to pregnancy, including a fall in systemic vascular resistance, rise in cardiac output, development of attenuated pressor responses, and the exponential rise in UtBF in the last third of gestation.

When administrated in intact or ovariectomized (OVX) NP sheep, E₂β can cause blood flow to rise in several organs throughout the body with the greatest effects occurring in reproductive tissues, especially the uterus. The selective uterine vasodilatory effect of estrogens is, however, with no doubt, of major physiological significance during pregnancy-associated UA dilation because circulating estrogens are significantly elevated in pregnancy. Plasma levels of total estrogens are ~300 pM in the secretory phase, rise to ~1000 pM in the proliferative phase, and aggressively increases with advancing gestation and concentrations just before parturition can reach as much as 1000 times greater to that of early gestation. UtBF rises sharply with elevated endogenous estrogens in the follicular phase and pregnancy, providing the evidence of a physiological role of endogenous estrogens in uterine vasodilation. Furthermore, daily E₂β (1 µg/kg body weight) treatment increases baseline UtBF by 30%–45% for up to 10 days in intact and OVX NP ewes; acute E₂β treatment provokes rapid (20–30 minutes) and even more robust up to 10-fold rise in UtBF within 90–120 minutes. Thus, these physiological and pharmacological studies have provided convincing evidence for the uterine potent vasodilatory effects of estrogens.
Estrogen receptors (ERs) and estrogen-induced UA dilation

Blockade of estrogen actions using the ER antagonist ICI 182,780 inhibits exogenous estrogen-induced rise in UtBF in OVX sheep by ~70% and endogenous estrogen-induced UA dilation in the follicular phase and pregnant ewes by 35%–40%. These studies established a primary proximal physiologic cause and effect relationship between endogenous estrogen-mediated ER activation and estrogen-induced UA dilation.

The biological functions of estrogens are known to be elicited by signaling via multiple ERs including ERα and ERβ and G protein-coupled ER (GPR30/GPER). The vascular effects of estrogens are mediated by both “genomic” and “nongenomic” pathways, such as ERα, ERβ, and GPER, which are found in ECs and SMCs in various vascular beds, including sheep UA. The genomic pathway is mediated by ERα/ERβ in the nucleus of target cells, whereas the ligated receptors function as ligand-activated transcription factors to regulate gene expression via interactions with estrogen-responsive elements (EREs) in the gene promoter or crossstalk between ligated ERs with other ERE-interacting transcription factors. The nongenomic estrogen signaling is mediated by plasma membrane ERs (ERα, ERβ, and GPER), which activate downstream proteins to elicit biological functions or nuclear transcription factors to regulate latent gene expression. Moreover, estrogen signaling can be even more complicated by the different and even opposite roles that ERα and ERβ may play in regulating cellular responses to estrogens, depending on cell types and cellular microenvironment.

GPER has been regarded as a specific membrane ER. Although GPER interacts with E2β with estimated binding affinities of 3–6 nM, this is much lower as compared with its binding affinities for classical ERs that are in the range of 0.1–1.0 nM. GPER also interacts with anti-estrogens such as tamoxifen and the non-specific ER antagonist ICI 182,780, as well as many other ER modulators, which makes it difficult to elucidate the specific role of GPER in target cells. Thus, the development of specific pharmacological tools, including highly selective GPER agonist G1 and antagonist G15, has greatly facilitated the characterization of GPER function. GPER binds ER with high affinity (Kd = 10 nM) without binding to ERα/β at concentrations as high as 10 µM, whereas G15, with a similar structure as G1, but lacks the ethanone moiety that forms hydrogen bonds involved in receptor activation, displays a Kd > 10 µM for binding ERα/β.

Both ERα and ERβ are expressed in ovine and human UAs and their expression has been shown to be differentially regulated in pregnancy. ERβ is preferentially upregulated in pregnant UA. Pregnancy augmented UA ER expression may be due to elevated endogenous estrogens because UA ER in OVX NP sheep and rats can be stimulated by exogenous E2β in vivo and by E2β treatment of UA rings from NP ewes in vitro. In an ex vivo study using wire myography to examine the specific roles of ERα and ERβ in estrogen-induced vasodilation in human UA and placental arteries, E2β treatment and activation of ERα by its specific agonist PPT (1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole) or ERβ by its specific agonist DPN (2,3-bis(4-hydroxyphenyl) propionitrile) provoke significant and similar relaxation effects in myometrial arteries. In contrast, E2β and DPN are less effective in relaxing placental arteries than that in myometrial arteries; whilst PPT was ineffective. The small arteries isolated from myometrial biopsies used in the study do not answer a question regarding the specific roles of ERα and ERβ in the response of the main UA to estrogens. However, these findings demonstrate that ERα and ERβ display vascular bed-specific roles in mediating the acute vasodilatory responses of estrogens in the human maternal-fetal interface vasculatures.

GPER is also expressed in various arteries including pregnant UA in rats. In humans, G1 relaxes human internal mammary artery ex vivo, but is unable to relax pressurized human myometrial and placental arteries ex vivo in myography studies. However, activation of GPER by E2β or G1 can result in a pregnancy-dependent decrease in uterine vascular tone in uterine radial artery via activating NO/cyclic guanosine monophosphate (cGMP) pathway in rats. These studies suggest that GPER displays vascular-bed and potentially species-dependent vascular effects of estrogens in the uterine and systemic vascular beds. Nonetheless, the specific roles of the classical ERs and ERβ and membrane GPER in estrogen-induced and pregnancy-associated uterine vasodilation remain to be incompletely understood, although the process has been shown to be clearly mediated by specific ER-dependent mechanisms in sheep models in vivo.

Estrogens and uterine vascular maladaptation to preeclampsia

Preeclampsia is a human pregnancy disorder clinically defined as new onset hypertension and proteinuria, and often with edema after the 20th week of gestation. Approximately 10 million pregnant women develop preeclampsia annually in the world, raising perinatal mortality ~5-fold, causing death of 45,000 babies in the United States alone and killing approximately 76,000 pregnant women worldwide. Preeclampsia predisposes the mother and her child to a significantly higher risk in metabolic diseases such as cardiovascular and diabetes later in life, representing a major public health threat.

The pathogenesis of preeclampsia remains partially understood but this is believed to be a two-stage disease composed of: (1) perturbation in placentation in the first trimester due to shallow trophoblast invasion and impaired spiral artery (the distal branch of UA vascular tree) remodeling and (2) constrained UtBF lead to placenta ischemia/hypoxia that further stimulates placental production of harmful factors, which in turn result in maternal inflammation and uterine and systemic EC damage/vascular dysfunction. Nonetheless, in patients with preeclampsia, the UA flow velocity decreases by ~26%, and uteroplacental perfusion is reduced by ~50%, as a result of increased vascular resistance compared with normal pregnancy. This clearly suggests that maternal and fetal well-being during pregnancy and after birth is largely controlled at the level of UtBF, making studies of uterine...
hemodynamics to hold high promise to inform pathways and targets for developing treatments for preeclampsia and IUGR.

In primates and human pregnancy, estrogens are mainly produced by the placenta to promote angiogenesis and vasodilation, which are two key mechanisms to cause UtBF to rise.14,16,49 Estrogen synthesis is greatly decreased in pregnant women with preeclampsia.50 Estrogen metabolism is also dysregulated in preeclamptic women.50 Mice lacking catechol-O-methyltransferase (the enzyme that converts E2β to catechol-estrogens) develop preeclampsia-like symptoms; supplementation of estrogens can lessen the preeclampsia phenotype in pregnant catechol-O-methyltransferase−/− mice.51 Thus, aberrant production and metabolism of estrogens play a key role in the pathogenesis of preeclampsia.

Current treatments for preeclampsia aim to normalize blood pressure rather than targeting the placenta pathology, but none is satisfactory; hypertension is reduced transiently, allowing Caesarean delivery to be set up. Delivery before term remains the only current effective treatment for severe preeclampsia, clearly testifying urgent unmet medical needs for patients with preeclampsia. In theory, it must be very difficult to develop therapeutics for preeclampsia by targeting placenta defects since a fully functional human placenta forms around week 15 in gestation before clinical manifestations of preeclampsia are diagnosed at the 20th week of gestation.52 Since resistant myometrial UA (radial and arcuate arteries) plays a key role in regulating maternal blood pressure during pregnancy,53 improving UtBF provides the most attractive target for managing clinical preeclampsia (ie, hypertension) so that gestation can be extended to avoid premature delivery. Unfortunately, clinical trials targeting NO signaling or other known pathways to improve UtBF and uterine perfusion have hitherto achieved no or little success in preeclampsia,54 urging more studies to identify new pathways.

**Estrogen-induced uterine vasodilation in pregnancy by the NO pathway**

Many investigators have attempted to address the mechanisms underlying the vasodilatory effects of estrogens in the uterine vasculature since the 1970s. It was, however, until the discovery of NO as the endothelium-derived vasodilator in the 1980s that a major pathway was identified for estrogen-induced uterine vasodilation. Endogenous NO is synthesized from L-arginine by a family of NO synthases (NOS), including endothelial NOS (eNOS/NOS3), neuronal NOS (nNOS/NOS2), and inducible NOS (iNOS). Endothelium-derived NO diffuses into the surrounding SMC where it activates the soluble guanylyl cyclase (sGC) to generate the second messenger cGMP; increased cGMP further activates protein kinase G (PKG) to relax blood vessels, thus resulting in vasodilation and increasing blood flow.55 Van Buren et al.56 first reported that when infused intraarterially into the UA, a non-specific NOS inhibitor N^o^-nitro-L-arginine-methyl ester (L-NAME) dose-dependently decreases the maximum E2β-induced increase in UtBF in sheep. Many follow-up studies not only confirmed this major finding but also reported that estrogen-induced rise in UtBF requires increased production of cGMP.3,57 The role of the NO/cGMP pathway in uterine vasodilation has promoted significant interest in perinatal research, and numerous studies have concluded that the NOS enzyme responsible for pregnancy- and agonist (estrogens)-stimulated UA NO production is primarily eNOS, which is exclusively expressed in the EC in all species studied, including sheep,51,57 mice,58,59 rats,59 nonhuman primates, and women.60 UA endothelial eNOS expression is upregulated by exogenous estrogens in OVX animals receiving estrogen replacement therapy and elevated endogenous estrogens during pregnancy, which is mediated by genomic estrogen signaling to upregulate eNOS transcription via nuclear ERα interactions with the ERs in eNOS promoter.61 In addition, ERα is present on the plasma membrane caveola of UC ECs,26,31,63 mediating estrogen-stimulated rapid (within minutes) NO production via eNOS phosphorylation via extracellular signal-activated kinases1/52 and possibly protein kinase B (PKB/Akt).50

Numerous studies have also demonstrated that the eNOS-derived NO is a focal mediator of uterine vasodilation since NO acts downstream of numerous UA dilators including estrogens, vascular endothelial growth factor, and angiotensin II (reviewed by Bai et al.52). The role of UA endothelium eNOS-derived NO in estrogen-induced and pregnancy-dependent rise in uterine vasodilation leads to increased cGMP production which in turn results in activation of various potassium channels such as ATP-dependent (K_ATP), voltage-dependent (Kv), and large conductance calcium-activated and voltage dependent (BKCa) potassium channels.62 However, infusion of BKCa blockers, but not other K+ channel blockers, intraarterially in UA significantly blocks estrogen-induced and baseline pregnancy-associated rises in UtBF in sheep,64 suggesting a primary role of SMC BKCa downstream of eNOS-NO/cGMP in regulating uterine hemodynamics.

BKCa channels are tetramers of the α subunit (BKα), which can be complemented with the regulatory subunits, including the β (1–4) and γ (1–4) isoforms.55 BKβ1 subunit is essential for increasing voltage sensitivity when intracellular free Ca2+ is beyond 1 μM.65 The γ1–γ4 are auxiliary subunits that greatly enhance channel properties in mammalian cells.67 The expression and their physiological and pathological functions of SMC BKCa channels have been well-studied in other tissues in mammalians,68 but their distribution and function remain to be explored in UA SMC. Previous studies have shown UA SMC expression of α and β1 and γ1–γ4 of BKCa.69 BKα is constitutively expressed, whereas pregnancy and estrogen significantly upregulate BKβ1 expression in UA.71 BKγ1 is upregulated 7-fold in mouse UA in pregnancy and female mice lacking BKγ1 gene is with blunted UA dilation and develops preeclampsia-like conditions during pregnancy.70 Other BK subunits, including B3, B4, and γ2–3 mRNAs are also detected in pregnant human UA and cultured primary human UA SMC.72 However, the role of these subunits in UA SMC BKCa activation pertaining to estrogen-induced UA dilation in pregnancy is unknown.

UtBF is reduced and placental vasculization is deranged in eNOS-deficient mice in association with impaired spiral artery remodeling and IUGR.58,73 Animals treated with L-NAME to inhibit endogenous NO production develop preeclampsia-like symptoms.74 These studies show
a causal role of dysregulated NO signaling in uterine and placental hemodynamics, forming the foundational knowledge base that has provoked many clinical trials to explore the NO pathway as a potential therapy for preeclampsia; and many preclinical and clinical trials have been performed through increasing endogenous NO production via L-arginine supplementation or decreasing NO metabolism by suppressing cyclic nucleotide phosphodiesterases that breaks down cGMP. A beneficial effect of L-arginine was confirmed in seven controlled randomized trials in which L-arginine supplementation significantly reduces the risk of pregnant women with established or suspected preeclampsia. Bolstering endogenous NO signaling using a phosphodiesterase 5 inhibitor Sildenafil (Viagra) and its derivatives have been extensively studied for treating preeclampsia. Sildenafil promotes a significant increase in UtBF in rats and has shown promising results in many preclinical studies in animal models of preeclampsia. In human studies, gestation is extended for 4 days in severe preeclamptic patients. However, a most recent clinical trial shows beneficial effects of sildenafil in treating pregnant women with a high risk of IUGR, but unfortunately, the trial has been halted because infants born from women receiving the drug died from pulmonary hypertension.

Hydrogen sulfide (H₂S) and estrogen-induced and pregnancy-associated uterine vasodilation

As mentioned above, numerous clinical trials targeting all known pathways controlling uterine vasodilation have hitherto only achieved no to little success in preeclampsia and IUGR, urging more studies to search for new pathways underlying uterine hemodynamic regulation. Of note is that the dominating NO/cGMP pathway only partially accounts for estrogen-induced and pregnancy-associated uterine vasodilation since t-NAME inhibits at most ~70% estrogen-induced rise in UtBF and ~25% baseline pregnancy-associated rise in UtBF in sheep in vivo. These studies clearly suggest that mechanisms in addition to NO are involved in mediating estrogen-induced uterine vasodilation in pregnancy. To this end, our recent studies have shown that enhanced H₂S serves as a novel UA dilator that may be accountable for the mechanisms behind NO to comprehend uterine hemodynamic regulation.

Endogenous H₂S is synthesized from L-cysteine by two pyridoxal-5'-phosphate-dependent enzyme cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) of the trans-sulfuration pathway. H₂S is now accepted as the gasotransmitter that is, 3-mercaptopyruvate sulfurtransferase and cysteine aminotransferase. A slow-releasing H₂S donor GYY4237 dose-dependently relaxes phenylephrine-precontracted UA rings from both pregnant and non-pregnant rats, but with significantly greater potency in the pregnant state. Moreover, the vasodilatory effect of H₂S in pregnancy is potentially vascular bed-specific because GYY4237 does not dilate mesenteric artery in pregnant rats. The H₂S donor also dose-dependently dilates pregnant UA in women ex vivo. Thus, these findings show that exogenous H₂S can stimulate pregnancy-dependent UA vasodilation, directly supporting H₂S as the new UA vasodilator.

The stimulatory effects of estrogens on UA EC and SMC CBS mRNA and protein expression in NP OVX sheep, estrogen replacement therapy stimulates EC/SMC CBS upregulation without altering CSE and other H₂S synthesizing enzymes, that is, 3-mercaptopyruvate sulfurtransferase and cysteine aminotransferase. However, in OVX NP sheep, estrogen replacement therapy stimulates UA H₂S production in association with SMC and EC CBS upregulation without altering CSE expression in vivo. Moreover, UA H₂S production is significantly augmented in association with elevated endogenous estrogens in the follicular/proliferative phase and pregnancy in ewes and women, with EC/SMC CBS upregulation without altering CSE and other H₂S synthesizing enzymes.

Thus, endogenous H₂S is also an important regulator of pregnancy. Significant findings show that exogenous H₂S can stimulate pregnancy-dependent UA vasodilation, directly supporting H₂S as the new UA vasodilator.

Interestingly, E₂β can stimulate rapid (within minutes) H₂S production in cultured human umbilical cord EC, which is achieved by EREs interactions with Gα12/13 on the plasma membrane, resulting in activation of GC/cGMP which in turn can phosphorylate CSE to increase H₂S production. Importantly, blocking the pathway can blunt estrogen-induced aorta vasodilation in mice, suggesting that activation of plasma membrane EREs-mediated nongenomic activation of endothelial CSE/H₂S production plays a role in estrogen-induced systemic vasodilation. In addition, CBS phosphorylation on serine by PKG also results in enzyme activation and increased H₂S production. Whether GPER or ERβ also play a role in the nongenomic activation of CSE/CBS remains to be explored. Although it is not reported whether estrogen stimulates rapid H₂S biosynthesis in UA EC and SMC, it is
warranted to determine if nongenomic estrogen signaling leading to CBS and/or CSE phosphorylation and activation thereby increasing H2S production is a mechanism to contribute to the initiation of estrogen-induced rise in UtBF within 15–30 minutes in animal models.21,93,94

Activation of SMC K_ATP channels was the first mechanism reported to mediate the vasodilatory effect of H2S in systemic arteries.93 However, we have recently reported that H2S stimulates relaxation of human UA and rat vas deferens via activating SMC BKCa channels without activation of K_ATP channels,72,96,97 although how H2S activates BKCa channels needs to be determined.

Human IUGR is associated with reduced uterine spiral artery CSE expression,98 suggesting that H2S signaling is impaired in pregnancy complications associated with reduced UtBF. Pregnancy also upregulates placental trophoblast H2S production, which is a placental vasodilator,98 and angiogenesis promoter94 and maintains early pregnancy via regulating maternal-fetal interface immune hemostasis.94 It is also well-documented that pregnancy-upregulated placental CBS/CSE-H2S signaling is reduced in preeclampsia.99 Importantly, in animal models of preeclampsia induced by overexpression of soluble vascular endothelial growth factor (VEGF) receptor 1 (soluble fms-like tyrosine kinase-1, sFlt1) to disrupt vascular endothelial growth factor signaling, H2S donors can rescue the animals from developing new onset hypertension and proteinuria and partially restored IUGR.100 These promising findings show a great potential of targeting H2S signaling to treat preeclampsia. However, research in H2S in uterine hemodynamics is still in its very early stage. More investigations are needed to determine a definite physiological role of enhanced H2S signaling in uterine vascular adaptation in normal pregnancy and a pathophysiological role of dysregulated H2S signaling in preeclampsia and other pregnancy complications.

**Summary**

Estrogen-induced uterine vasodilation in pregnancy is mediated by ER-dependent augmentation of local UA production of orchestrated vasodilators, among which NO has been in general considered to play a leading role. More recently, evidence has emerged to show that enhanced local UA H2S production is a novel UA dilator for mediating estrogen-induced uterine vasodilation in pregnancy and preeclampsia (Fig. 1). It is possible that H2S may play an even more important role than NO in mediating estrogen-induced uterine vasodilation because NO is produced by eNOS that is mainly expressed in EC while H2S is produced by CBS that is upregulated by both EC and SMC. H2S production is thus expected to be with a

---

**Figure 1.** NO and H2S mediated mechanisms modulating uterine vasodilation in pregnancy and preeclampsia. Normal pregnancy is associated with dramatically increased production of endogenous estrogens that raise UtBF. Estrogens increase specific receptor (ERα and ERβ)-dependent endothelium (EC) expression of eNOS to produce NO that has been recognized as a leading player to mediate estrogen-induced uterine vasodilation in pregnancy. Most recent emerging evidence also shows that estrogens stimulate ERα and ERβ dependent EC and SM expression of CBS to produce H2S. In addition, by binding with plasma membrane ER including caveolar ERα and the GPER, estrogen can stimulate rapid production of NO and possibly H2S by activating eNOS and CBS via posttranslational mechanisms such as phosphorylation by protein kinases including PKB (Akt), extracellular signal-activated kinases (ERK1/2), and PKG. Enhanced NO and H2S collectively open the large conductance calcium-activated and voltage-dependent potassium (BKCa) channels to hyperpolarize SM resulting in UA relaxation. In preeclampsia, estrogen production decreases and its metabolism is also impaired to further result in the deactivation of NO- and H2S-mediated mechanisms modulating uterine vasodilation that contributes to the clinical manifestations of preeclampsia. Words in bright color indicate stimulation and words in dimmed color indicate deactivation. CBS: Cystathionine β-synthase; cGMP: Cyclic guanosine monophosphate; EC: Endothelial cells; ER: Estrogen receptor; ERK1/2: Extracellular signal-activated kinases 1/2; eNOS: Endothelial NOS; GPER: G protein-coupled ER; H2S: Hydrogen sulfide; NO: Nitric oxide; NOS: NO synthases; PKB: Protein kinase B; PKG: Protein kinase G; SM: Smooth muscle; UA: Uterine artery; UtBF: Uterine blood flow.
much great quantity than NO production in UA upon estrogen stimulation in pregnancy, considering that the tube-shaped main UA is composed of a single layer of EC and multi-layer of SMCs. Clinical trials targeting the best-studied NO pathway have been essentially failed in treating preeclampsia, urging more studies necessitated to explore the therapeutic potential of H₂S in preeclampsia. Nonetheless, research on H₂S maternal physiology and placental biology is in its very early stage. Although a few studies have shown a beneficial effect of H₂S in animal models of preeclampsia, a clinical trial of H₂S in preeclampsia with IUGR will mostly become a reality when a physiological and pathophysiological role of H₂S can be established in future studies to provide a thorough understanding of the biosynthesis, metabolism, and mechanisms of action of H₂S during pregnancy and possibly systemic vascular adaptations to pregnancy and preeclampsia.

Funding
The present study was supported in part by the National Institutes of Health (NIH; grant numbers: R01 RO1 HL70562, HD105699, and R21 HD097498 to Dong-bao Chen). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

Conflicts of Interest
None.

References
[1] Palmer SK, Zamudio S, Coffin C, et al. Quantitative estimation of human uterine artery blood flow and pelvic blood flow redistribution in pregnancy. Obstet Gynecol 1992;80(6):1000–1006.
[2] Rosenfeld CR. Distribution of cardiac output in ovine pregnancy. Am J Physiol 1977;233(3):H231–H235. doi:10.1152/ajpheart.1977.233.3.H231.
[3] Magnes RR, Phernetton TM, Gibson TC, et al. Uterine blood flow responses to IC1 182 780 in ovariectomized oestriol-17β-treated, intact follicular and pregnant sheep. J Physiol 2005;565(Pt 1):71–83. doi:10.1113/jphysiol.2005.086439.
[4] Thornburg KL, Jacobson SL, Giraud GD, et al. Hemodynamic changes in pregnancy. Semin Perinatol 2000;24(1):11–14. doi:10.1053/spri.2000.0595.
[5] Yu CK, Khouri O, Onwudiwe N, et al. Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2009;31(3):310–313. doi:10.1002/uog.5252.
[6] Goulopoulou S. Maternal vascular physiology in preeclampsia. Hypertension 2017;70(6):1066–1073. doi:10.1161/HYPERTENSIONAHA.117.08821.
[7] Rosenfeld CR, Roy T, Cox BE. Mechanisms modulating estrogen-induced uterine vasodilation. Vascul Pharmacol 2002;38(2):115–125. doi:10.1016/s0144-0341(02)00081-3.
[8] Farrer-Brown G, Beilby JO, Tarbit MH. The blood supply of the uterus. 1. Arterial vasculature. J Obstet Gynaecol Br Commonwealth 1970;77(8):673–681. doi:10.1111/j.1471-0528.1970.tb03592.x.
[9] Oso G, Moore LG. Maternal uterine vascular remodeling during pregnancy. Microcirculation 2014;21(1):38–47. doi:10.1111/micc.12080.
[10] Bernstein IM, Ziegler WF, Leavitt T, et al. Uterine artery hemodynamic adaptations through the menstrual cycle into early pregnancy. Obstet Gynecol 2002;99(4):620–624. doi:10.1016/s0029-8444(01)01787-2.
[11] Ziegler WF, Bernstein I, Badger G, et al. Regional hemodynamic adaptation during the menstrual cycle. Obstet Gynecol 1999;94(3 Pt 1):695–699. doi:10.1016/s0029-8444(99)00397-x.
[12] Dogan O, Yildiz A, Temizkan O, et al. Comparison of uterine, endometrial and ovarian blood flow by transvaginal color Doppler ultrasound in ovulatory and anovulatory women. Gynecol Pol 2016;87(8):581–584. doi:10.5603/GP.2016.0048.
[13] Steer CV, Campbell S, Pampiglione JS, et al. Transvaginal colour flow imaging of the uterine arteries during the ovarian and menstrual cycles. Hum Reprod 1995;10(4):391–395. doi:10.1093/humrep/aer047.
[14] Albrecht ED, Pege GJ. Placental steroid hormone biosynthesis in primate pregnancy. Endocr Rev 1990;11(1):124–150. doi:10.1210/edrv-11-1-124.
[15] Pege GJ, Albrecht ED. Glob. Int Rev. Women’s Med. Steroid Endocrinology of Pregnancy (ISSN: 1756-2228) 2008. doi:10.3843/GOLOWM.10311.
[16] Magnes RR, Rosenfeld CR, Zheng J. Rosenfeld CR. The role of steroid hormones in the control of uterine blood flow. Uterine Circulation (Reproductive and Perinatal Medicine). Ithaca, NY: Perinatology Press; 1989;239–271. Vol 10, Issue 1.
[17] Magnes RR, Phernetton TM, Zheng J. Systemic and uterine blood flow distribution during prolonged infusion of 17beta-estradiol. Am J Physiol 1998;275(3):H731–H743. doi:10.1152/origin.1998.275.3.H731.
[18] Gibson TC, Phernetton TM, Wilfthus MC, et al. Development and use of an ovarian synchronization model to study the effects of endogenous estrogen and nitric oxide on uterine blood flow during ovarian cycles in sheep. Biol Reprod 2004;70(6):1886–1894. doi:10.1095/biolreprod.103.019901.
[19] Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians [published correction appears in Obstet Gynecol 2010 Feb;115(2 Pt 1):387]. Obstet Gynecol 2009;114(6):1326–1331. doi:10.1097/AOG.0b013e3181c2de8.
[20] Rosenfeld CR, Chen C, Roy T, et al. Estrogen selectively up-regulates ERα and nNOS in reproductive arteries by transcriptional mechanisms. J Soc Gynecol Investig 2003;10(4):205–215. doi:10.1016/S1071-5576(03)00049-2.
[21] Magnes RR, Rosenfeld CR. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. Am J Physiol 1998;275(3):H731–H743. doi:10.1152/ajpheart.1998.275.4.E536.
[22] Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011;109(6):687–696. doi:10.1161/CIRCRESAHA.110.236687.
[23] Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89(5):1943–1950. doi:10.1161/01.cir.89.5.1943.
[24] Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 1998;64(3–4):187–191. doi:10.1016/S0090-0767(97)00155-6.
[25] Tropea T, De Francesco EM, Riggiariccioli D, et al. Pregnancy augments G protein estrogen receptor (GPER) induced vasodilation in rat uterine arteries via the nitric oxide - cGMP signaling pathway. PLoS One 2015;10(11):e0141997. doi:10.1371/journal.pone.0141997.
[26] Liao WX, Magnes RR, Chen DB. Expression of estrogen receptors-alpha and -beta in the pregnant ovine uterine endothelial cells in vivo and in vitro. Biol Reprod 2005;72(3):530–537. doi:10.1093/biolreprod.104.03594.
[27] Byers MJ, Zangl A, Phernetton TM, et al. Endothelial vasodilator production by ovine uterine and systemic arteries: ovarian steroid and pregnancy control of ERAlpha and ERBeta levels. J Physiol 2005;565(Pt 1):85–99. doi:10.1111/j.1349-7241.2005.05225.x.
[28] Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006;20(9):1996–2009. doi:10.1210/me.2005-05225.
[29] Meyer MR, Prossnitz ER, Barton M. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 2011;55(1–3):17–25. doi:10.1016/j.vph.2011.06.003.
[30] Dimmeler S, Fleming I, Fischhaller B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399(6736):601–605. doi:10.1038/21224.
[31] Chen DB, Bird IM, Zheng J, et al. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 2004;145(1):113–125. doi:10.1210/en.2003-0547.
Leiberman JR, Meizner I, Mazor M, et al. Blood supply to the
trophoblast. Fetal Diagn Ther 2017;41(2):81–88. doi:10.1159/
000453062.

Mayer R, Schmidt K, Humbert P, et al. Biosynthesis of
di-oxygenase-derived relaxing factor: a cytosolic enzyme in porcine
aortic endothelial cells Cd-like–dependently converts L-arginine to
an activator of soluble guanylyl cyclase. Biochem Biophys Res
Commun 1989;164(2):678–685. doi:10.1016/0006-291x(89)
91513-1.

Van Buren GA, Yang DS, Clark KE. Estrogen-induced uterine
ersystolic blood flow in women with pre-eclampsia and their
preeclampsia. Science 2005;308(5728):1592–1594. doi:10.1126/science.1111726.

Adekunmi AJ, Roberts A, Akinmoladun JA, et al. Uterine and
pericardial artery remodeling in early human pregnancy.
Am J Pathol 2018;188(3):7917–7922. doi:10.1016/j.ajpath.2018.07.014.

Rosenfeld CR, Roy T, et al. Nitric oxide contributes to
estrogen-induced vasodilation of the ovine uterine circulation. J
Clin Invest 1996;99(9):2158–2166. doi:10.1172/JCI19022.

van der Heijden OW, Essers V, et al. Uterine artery remodeling and
reproductive performance are impaired in
endothelial nitric oxide synthase-deficient mice. Biol Reprod
2005;72(3):1161–1168. doi:10.1095/biolreprod.104.033985.

Cadmium-resistant MA, Ohara M, Morris KG Jr, et al. Chronic
NOS inhibition reverses systemic vasodilation and glomerular
hypertrophy in pregnancy. Am J Physiol Renal Physiol 2001;280
(4):F592–F598. doi:10.1152/ajprenal.2001.280.4.F592.

Okamura T, Ghomei H, Ayajiki K, et al. Mechanisms underlying contraction and relaxation induced by nerve stimulation in
monkey uterine arteries. Pharmacology 2000;61(4):251–256.
doi:10.1159/0000028409.

Kubickiene KR, Cockell AP, Nisell H, et al. Role of nitric oxide in
the regulation of vasomotor tone in pressurized and perfused
dilation of human uterine arteries. Uterine artery remodeling in nonpregnant human uterine arteries. Reprod Sci 2008;15
(7):651–660. doi:10.1177/1937190108319160.
Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: a whiff exploration that blossomed. Physiol Rev 2012;92(2):791–896. doi:10.1152/physrev.00017.2011.

Bao H, Zhang J, Zhu Z, et al. H2S and cystathionine-gamma-lyase are endogenous stimulators of angiogenesis. Proc Natl Acad Sci USA 2009;106(51):21972–21977. doi:10.1073/pnas.0908741106.

Chen DB, Feng L, Hodges JK, et al. Human trophoblast-derived hydrogen sulfide stimulates placental artery endothelial cell angiogenesis. Biol Reprod 2017;97(3):478–489. doi:10.1093/biolre/iox105.

Qi QR, Letchuga TJ, Patel B, et al. Enhanced stromal cell CBS-H2S production promotes estrogen-stimulated human endometrial angiogenesis. Endocrinology 2020;161(11):bqaa176. doi:10.1207/s15569123endo-110-4-1333. doi:10.1122/aphrre.00996.2013.

Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012;92(2):791–896. doi:10.1152/physrev.00017.2011.

Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008;322(5901):587–590. doi:10.1126/science.1162667.

Fappapetroupos A, Pirisouchou A, Altazy Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA 2009;106(51):21972–21977. doi:10.1073/pnas.0908741106.

Chen DB, Feng L, Hodges JK, et al. Human trophoblast-derived hydrogen sulfide stimulates placental artery endothelial cell angiogenesis. Biol Reprod 2017;97(3):478–489. doi:10.1093/biolre/iox105.

Li Y, Han B, Salmeron AG, Bai J, Chen DB. Endogenous-induced uterine vasodilation in pregnancy and preeclampsia. Maternal Fetal Med 2022;4(1):52–60. doi:10.1097/FMR.0001000000001052.

Edited By Dandan Shi